BALAXI PHARMA | BLUE PEARL TEXSPIN | BALAXI PHARMA/ BLUE PEARL TEXSPIN |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 11.7 | 5.1 | 228.8% | View Chart |
P/BV | x | 2.1 | - | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BALAXI PHARMA BLUE PEARL TEXSPIN |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BALAXI PHARMA Mar-24 |
BLUE PEARL TEXSPIN Mar-24 |
BALAXI PHARMA/ BLUE PEARL TEXSPIN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 686 | 44 | 1,551.7% | |
Low | Rs | 400 | 31 | 1,273.7% | |
Sales per share (Unadj.) | Rs | 221.4 | 10.2 | 2,180.2% | |
Earnings per share (Unadj.) | Rs | -2.2 | -2.7 | 82.5% | |
Cash flow per share (Unadj.) | Rs | -0.3 | -2.7 | 10.0% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 181.3 | -7.1 | -2,547.7% | |
Shares outstanding (eoy) | m | 10.90 | 0.26 | 4,192.3% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.5 | 3.7 | 67.0% | |
Avg P/E ratio | x | -248.0 | -14.1 | 1,754.7% | |
P/CF ratio (eoy) | x | -2,051.6 | -14.1 | 14,518.0% | |
Price / Book Value ratio | x | 3.0 | -5.2 | -57.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 5,919 | 10 | 61,145.3% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 280 | 0 | 107,826.9% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 2,413 | 3 | 91,399.2% | |
Other income | Rs m | 6 | 0 | - | |
Total revenues | Rs m | 2,419 | 3 | 91,639.0% | |
Gross profit | Rs m | 62 | -1 | -9,053.6% | |
Depreciation | Rs m | 21 | 0 | - | |
Interest | Rs m | 28 | 0 | - | |
Profit before tax | Rs m | 20 | -1 | -2,920.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 44 | 0 | - | |
Profit after tax | Rs m | -24 | -1 | 3,459.4% | |
Gross profit margin | % | 2.6 | -26.0 | -10.0% | |
Effective tax rate | % | 218.5 | 0 | - | |
Net profit margin | % | -1.0 | -26.0 | 3.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,102 | 5 | 44,908.5% | |
Current liabilities | Rs m | 542 | 7 | 8,017.3% | |
Net working cap to sales | % | 64.6 | -78.7 | -82.1% | |
Current ratio | x | 3.9 | 0.7 | 560.1% | |
Inventory Days | Days | 8 | 29 | 25.8% | |
Debtors Days | Days | 843 | 1,082,459 | 0.1% | |
Net fixed assets | Rs m | 482 | 0 | 209,439.1% | |
Share capital | Rs m | 109 | 3 | 4,257.0% | |
"Free" reserves | Rs m | 1,867 | -4 | -42,334.0% | |
Net worth | Rs m | 1,976 | -2 | -106,805.9% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 2,583 | 5 | 52,615.7% | |
Interest coverage | x | 1.7 | 0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.9 | 0.5 | 173.7% | |
Return on assets | % | 0.1 | -14.0 | -1.1% | |
Return on equity | % | -1.2 | 37.1 | -3.3% | |
Return on capital | % | 2.4 | 37.0 | 6.5% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 648 | 0 | - | |
Fx outflow | Rs m | 19 | 0 | - | |
Net fx | Rs m | 629 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 49 | 2 | 2,420.9% | |
From Investments | Rs m | -10 | NA | - | |
From Financial Activity | Rs m | 303 | 1 | 30,254.0% | |
Net Cashflow | Rs m | 341 | 3 | 11,320.3% |
Indian Promoters | % | 66.0 | 0.1 | 50,761.5% | |
Foreign collaborators | % | 0.0 | 19.5 | - | |
Indian inst/Mut Fund | % | 16.5 | 0.0 | 82,500.0% | |
FIIs | % | 16.5 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 34.0 | 80.3 | 42.3% | |
Shareholders | 7,863 | 8,390 | 93.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BALAXI PHARMA With: ADANI ENTERPRISES REDINGTON MMTC SIRCA PAINTS INDIA UNIPHOS ENT
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BALAXI PHARMA | E-WHA FOAM (I) | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -4.17% | 0.00% | 0.11% |
1-Month | -20.49% | 22.60% | -3.22% |
1-Year | -81.77% | 258.03% | 42.65% |
3-Year CAGR | -50.46% | 100.60% | 19.86% |
5-Year CAGR | -34.39% | 59.64% | 25.90% |
* Compound Annual Growth Rate
Here are more details on the BALAXI PHARMA share price and the E-WHA FOAM (I) share price.
Moving on to shareholding structures...
The promoters of BALAXI PHARMA hold a 66.0% stake in the company. In case of E-WHA FOAM (I) the stake stands at 19.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BALAXI PHARMA and the shareholding pattern of E-WHA FOAM (I).
Finally, a word on dividends...
In the most recent financial year, BALAXI PHARMA paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
E-WHA FOAM (I) paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of BALAXI PHARMA, and the dividend history of E-WHA FOAM (I).
For a sector overview, read our pharmaceuticals sector report.
On Thursday, Indian share markets traded lower throughout the trading session and ended on a weak note.